Annexon (NASDAQ:ANNX) Hits New 1-Year Low - Time to Sell?

Annexon logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Annexon shares hit a new 52-week low, trading as low as $3.14 and last at $3.245, down from the prior close of $3.41.
  • Analyst views are mixed: the consensus rating is Hold, with an average price target of $13.33; five analysts rate the stock Buy, two Hold, and two Sell.
  • Annexon reported a quarterly loss of $0.25 per share, beating estimates of a $0.28 loss. CEO Douglas Love also bought 26,065 shares at an average price of $3.83.
  • MarketBeat previews top five stocks to own in December.

Shares of Annexon, Inc. (NASDAQ:ANNX - Get Free Report) reached a new 52-week low on Friday. The company traded as low as $3.14 and last traded at $3.2450, with a volume of 348,991 shares changing hands. The stock had previously closed at $3.41.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ANNX. Citizens Jmp upgraded shares of Annexon from an "underperform" rating to a "market perform" rating in a research report on Thursday, August 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Annexon in a research report on Thursday, October 15th. Wall Street Zen downgraded shares of Annexon from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Annexon from $14.00 to $15.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 30th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Annexon presently has a consensus rating of "Hold" and an average target price of $13.33.

Read Our Latest Report on ANNX

Annexon Stock Down 5.4%

The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.79 and a current ratio of 5.79. The company's 50-day moving average price is $3.94 and its 200 day moving average price is $5.05. The stock has a market capitalization of $615.39 million, a P/E ratio of -3.12 and a beta of 1.43.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.03. As a group, equities analysts expect that Annexon, Inc. will post -1.03 earnings per share for the current year.

Insider Buying and Selling

In other Annexon news, CEO Douglas Love purchased 26,065 shares of the company's stock in a transaction on Thursday, September 24th. The stock was acquired at an average cost of $3.83 per share, for a total transaction of $99,828.95. Following the purchase, the chief executive officer directly owned 390,476 shares of the company's stock, valued at $1,495,523.08. This trade represents a 7.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.31% of the company's stock.

Hedge Funds Weigh In On Annexon

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Redmile Group LLC grew its stake in Annexon by 44.8% during the first quarter. Redmile Group LLC now owns 14,549,768 shares of the company's stock valued at $80,606,000 after acquiring an additional 4,499,124 shares in the last quarter. BlackRock Inc. bought a new position in shares of Annexon during the 2nd quarter valued at about $77,312,000. Bank of America Corp DE boosted its holdings in shares of Annexon by 165.3% during the 1st quarter. Bank of America Corp DE now owns 4,259,995 shares of the company's stock valued at $23,600,000 after purchasing an additional 2,654,414 shares during the last quarter. Siren L.L.C. bought a new position in shares of Annexon during the 1st quarter valued at about $21,931,000. Finally, Palo Alto Investors LP purchased a new position in shares of Annexon during the second quarter valued at about $16,833,594.

About Annexon

(Get Free Report)

Annexon is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively. Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Annexon Right Now?

Before you consider Annexon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.

While Annexon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines